SCHEMBL3018334

SCHEMBL3018334

O=[N+]([O-])c1cc(S(=O)(=O)C2CCN(c3nc(-c4ccc(F)c(F)c4)cs3)CC2)ccc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 10/20 0.44
MAPT P10636 5/20 0.44
ALDH1A1 P00352 3/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
RAB9A P51151 7/20 0.42
NPC1 O15118 6/20 0.42
KMT2A Q03164 4/20 0.42
MEN1 O00255 3/20 0.42
POLB P06746 2/20 0.42
AR P10275 1/20 0.42
USP2 O75604 1/20 0.39
RECQL P46063 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MAPK1 P28482 1/20 0.39
VCAM1 P19320 1/20 0.39
EIF4E P06730 1/20 0.38
NPBWR1 P48145 1/20 0.38
MCHR1 Q99705 1/20 0.38
LMNA P02545 1/20 0.38
CYP1A2 P05177 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3010842 0.96 SMN1; SMN2 (0.45) SMN1; SMN2MAPTALDH1A1L3MBTL1RAB9A
SCHEMBL3016899 0.95 SMN1; SMN2 (0.44) SMN1; SMN2MAPTALDH1A1L3MBTL1RAB9A
SCHEMBL3009863 0.91 AR (0.52) SMN1; SMN2MAPTALDH1A1L3MBTL1RAB9A
SCHEMBL3012914 0.90 SMN1; SMN2 (0.46) SMN1; SMN2MAPTALDH1A1L3MBTL1RAB9A
SCHEMBL3018845 0.90 SMN1; SMN2 (0.46) SMN1; SMN2MAPTALDH1A1L3MBTL1RAB9A
SCHEMBL3009658 0.89 AR (0.51) SMN1; SMN2MAPTALDH1A1L3MBTL1RAB9A
SCHEMBL3016292 0.89 SMN1; SMN2 (0.43) SMN1; SMN2MAPTALDH1A1L3MBTL1RAB9A
SCHEMBL3003230 0.88 SMN1; SMN2 (0.49) SMN1; SMN2MAPTALDH1A1L3MBTL1RAB9A
SCHEMBL3005817 0.88 EGFR (0.43) SMN1; SMN2MAPTALDH1A1L3MBTL1RAB9A
SCHEMBL3008599 0.88 MAPK1 (0.47) SMN1; SMN2MAPTALDH1A1L3MBTL1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885MAPT 18/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.